Jennifer Cutler provides counsel to corporate clients on public and government relations strategies, drawing on her experience in state and federal legislative affairs, grassroots management, coalition building, and strategic communications. Jennifer specializes in the telecommunications and technology sectors and has extensive experience in creating and executing public affairs strategies on high profile industry issues. She also has first-hand experience leading winning advocacy campaigns across a variety of policy issues, including tax reform, trade and health care. Prior to joining DCI in 2005, Jennifer served as Vice President and Political and Research Director of McAuliffe Message Media (M3), a top media consulting firm specializing in political messaging, strategy, and media. Jennifer is a graduate of Boston University where she earned a Masters in Mass Communication with a focus on qualitative and quantitative research. Also at Boston University, Jennifer received a Bachelor of Arts in Political Science and a Bachelor of Science in Public Relations. While studying at Boston University, Jennifer interned on a presidential campaign and for a market research company in London, United Kingdom.
Topics
Appearances (1)
2026-08-27
Psychedelics in Mental Health: From Clinical Trials to State LinesIn this episode, Jennifer Cutler, a partner at DCI Group, discusses the evolving landscape of psychedelic treatments for mental health issues. She highlights the FDA's role in approving various psychedelic products aimed at conditions like PTSD and depression, while emphasizing the challenges states face in implementing these therapies after federal approval. Cutler notes the bipartisan support for mental health initiatives, particularly for veterans, and identifies states like Colorado and Illinois as leaders in legislative progress regarding psychedelic-assisted therapy.
Notable quotes
“Mental health continues to be a serious issue in this country. And over 14 million Americans live with a serious mental illness.”
“It's about 25 years of patients having essentially the same treatment options, though, you know, there's finally a serious wave of innovative new psychiatric medicines using psychedelics moving through the FDA.”
“FDA approval is a huge milestone, but by itself, it does not put a medication in patients' hands, especially not for controlled substances.”
“If a state hasn't done any of this groundwork in advance, here's what's going to happen: the FDA is going to approve a drug, patients are going to start hearing about it, but if the legislature isn't meeting for another 6 months, these patients aren't going to have access.”
“When people hear the word psychedelic, you're thinking we're going to go to Woodstock or a festival, which makes sense because that's really how cultural TV, movies, et cetera, have associated with that word for the past 50 years.”
“This is a very, very bipartisan issue... Mental illness does not care about your political party, doesn't care about your state.”
